Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odintsov

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
Nature Medicine|March 20, 2024
A visual-language foundation model for computational pathologyMing Y Lu, Bowen Chen, Drew F K Williamson, et al.
Voprosy Virusologii|July 12, 2023
[Development and preservation of specific T-cell immunity after COVID-19 or vaccination against this infection]M S Blyakher, I M Fedorova, E A Tulskaya, et al.
Communications Biology|December 17, 2020
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitorsRomel Somwar, Nicolle E Hofmann, Bryan Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2021
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive CancersIgor Odintsov, Marissa S Mattar, Allan J W Lui, et al.
JCO Precision Oncology|June 4, 2019
Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung CancerKen Suzawa, Michael Offin, Adam J Schoenfeld, et al.
The American Journal of Surgical Pathology|March 26, 2026
FOS and FOSB Immunohistochemistry and Molecular Testing Reveal Novel Patterns in Proliferative Fasciitis and Myositis, FOSB Rearrangement in Proliferative Funiculitis, and FOSL1::RELA Fusion in Pediatric Proliferative FasciitisSanhong Yu, Fleur Cordier, Esther Baranov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2021
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> FusionsIgor Odintsov, Allan J W Lui, Whitney J Sisso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2023
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLCIgor Odintsov, Maisam Makarem, Mizuki Nishino, et al.
JCO Precision Oncology|September 11, 2024
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> AmplificationArielle Elkrief, Igor Odintsov, Roger S Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2023
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting StrategiesHibiki Udagawa, Monique B Nilsson, Jacqulyne P Robichaux, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Nature Medicine|March 20, 2024
A visual-language foundation model for computational pathologyMing Y Lu, Bowen Chen, Drew F K Williamson, et al.
Voprosy Virusologii|July 12, 2023
[Development and preservation of specific T-cell immunity after COVID-19 or vaccination against this infection]M S Blyakher, I M Fedorova, E A Tulskaya, et al.
Communications Biology|December 17, 2020
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitorsRomel Somwar, Nicolle E Hofmann, Bryan Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2021
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive CancersIgor Odintsov, Marissa S Mattar, Allan J W Lui, et al.
JCO Precision Oncology|June 4, 2019
Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung CancerKen Suzawa, Michael Offin, Adam J Schoenfeld, et al.
The American Journal of Surgical Pathology|March 26, 2026
FOS and FOSB Immunohistochemistry and Molecular Testing Reveal Novel Patterns in Proliferative Fasciitis and Myositis, FOSB Rearrangement in Proliferative Funiculitis, and FOSL1::RELA Fusion in Pediatric Proliferative FasciitisSanhong Yu, Fleur Cordier, Esther Baranov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2021
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> FusionsIgor Odintsov, Allan J W Lui, Whitney J Sisso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2023
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLCIgor Odintsov, Maisam Makarem, Mizuki Nishino, et al.
JCO Precision Oncology|September 11, 2024
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> AmplificationArielle Elkrief, Igor Odintsov, Roger S Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2023
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting StrategiesHibiki Udagawa, Monique B Nilsson, Jacqulyne P Robichaux, et al.
Pageof 20